26 June 2025 in The Journal Of Prevention of Alzheimer's Disease
Cognitive aging is a growing public health concern, and curcumin, a bioactive compound derived from turmeric, has been proposed as a potential intervention to support cognitive function due to its anti-inflammatory and antioxidant properties. This systematic review and meta-analysis aimed to evaluate the effects of curcumin on cognitive outcomes related to aging. A comprehensive search of PubMed, Embase, Cochrane Library, Web of Science, and Scopus was conducted to identify studies published up to June 18, 2024, including both in vivo preclinical animal studies and randomized controlled trials (RCTs) assessing curcumin's effects on cognitive function. In vivo animal studies using Alzheimer's disease (AD) models and RCTs in human participants were included. Data were extracted and analyzed using meta-analytic techniques. In preclinical in vivo murine studies (n = 25; total animals = 572), curcumin consistently improved both acquisition memory (SMD = -1.78, 95 % CI: -2.12 to -1.43) and retention memory (SMD = 2.36, 95 % CI: 1.72 to 3.00) in rodent models of AD. Ten human studies include 531 participants. Overall, curcumin showed no significant effect on global cognitive outcomes compared to placebo (SMD = 0.14, 95 % CI: -0.78 to 1.07). Subgroup analyses revealed significant improvements in working memory (SMD = 1.01, 95 % CI: 0.15 to 1.87) and processing speed (SMD = 0.37, 95 % CI: 0.07 to 0.67). The incidence of adverse events was higher in the curcumin group than in the control group. Preclinical in vivo evidence suggests curcumin enhances cognitive function in AD models. However, human studies show inconsistent findings with benefits limited to specific cognitive domains. Larger, well-designed randomized controlled trials are needed to establish curcumin's efficacy and safety in cognitive aging.
12 September 2025 in General Psychiatry
With the expansion of the ageing population, cognitive decline has become an increasingly pressing challenge. 1 As life expectancy increases, its socioeconomic burden is also increasing, highlighting the urgent need for effective interventions. Numerous studies suggest that specific dietary patterns and nutritional interventions may help mitigate cognitive decline associated with ageing.2 Among these, caloric restriction (CR), which aims to extend lifespan through reduced calorie intake, has gained significant research interest in recent years.3 However, the optimal CR regimen remains difficult to define due to the risk of malnutrition and other potential adverse effects. Moreover, maintaining long-term adherence to CR can be difficult for most individuals. Consequently, the use of caloric restriction mimetics (CRMs), compounds that replicate the physiological benefits of CR without requiring stringent dietary modifications, has emerged as a promising and potentially practical alternative. Among these, increasing evidence suggests that CR and intermittent fasting may elevate endogenous levels of spermidine (SPD), a polyamine compound now being investigated as a natural CRM candidate.4